Director, Division of Colorectal Surgery, Jewish General Hospital and McGill University
Professor, Departments of Surgery and Oncology, McGill University
Dr. Philip Gordon is Director of the Division of Colorectal Surgery at the Jewish General Hospital and McGill University. He is an internationally recognized colorectal surgeon who served as President of the American Society of Colorectal Surgeons (ASCRS) (1994-95), President of the American Board of Colon and Rectal Surgeons, and was founding President of the Canadian Society of Colorectal Surgeons (1982-86), and Vice Chairman - Advisory Council for Colon and Rectal Surgery, American College of Surgeons from 1992 to 1995. Dr. Gordon is proud of his role as the first Canadian president of the ASCRS, the premier society of colorectal surgeons, and of having helped to found its Canadian equivalent, in which he continues to play an active role.
He is well-known for his numerous contributions to colorectal surgery, not least of which includes the co-authorship of one of the two leading textbooks on colorectal surgery, which is in its third edition. He is also co-author of the major textbook on cancer of the lower alimentary tract, which is in its second edition. From a research perspective, he has over 140 publications and has contributed to studies on genetic predisposition to colorectal cancer and to the effective treatment of numerous neoplastic and non-neoplastic disorders of the colon and rectum.
Among other distinctions, he is has been an invited participant at countless colorectal surgical meetings, and has given nine named lectureships in Canada, the United States, and Australia. In 2009, he was honoured by the Jewish General Hospital, which bestowed the 46th Annual André Aisenstadt Memorial Clinical Day to him for his “devotion and dedication to the advancement of colorectal surgery locally, nationally and internationally.”
Major Research Activities
Dr. Gordon continues to support research into genetic causes of colorectal cancer, and collaborates extensively with the genetics group at the Lady Davis Institute. Another major collaborative research interest includes the development of a mouse model for colorectal carcinoma. Using the gene that is responsible for hereditary non-polyposis colorectal carcinomam, HMLH1, he has successfully developed a tissue conditional Cre knockout HMLH1mouse. When crossed with the appropriate mice he will have a mouse model for colorectal carcinoma which will enable further investigation of the genetic alterations that lead to colon cancer. This can provide a much better insight into the cause of the disease. The mouse model will also serve as an excellent platform on which new anti-cancer drugs can be tested.
DiFabio F, Shrier I, Begin LR, Gordon PH. Absence of prognostic Value of Nuclear Shape Factor Analysis in Colorectal Carcinoma: Relevance of Interobserver and Intraobserver Variability. Dis Colon Rectum 2008:51:1781-5.
DiFabio F, Obrand D, Satin R, Gordon PH. Intra-abdominal Venous and Arterial Thromboembolism in Inflammatory Bowel Disease. Dis Colon Rectum 2009:52:336-42.
Chong G, Jarry J, Marcus V, Thiffault I, Winocour S, Ouellette G, Drouin R, Latreille J, Australie K, Bapat B, Gorska I, Gordon PH, Giguère Y, Gologan A, Galiatsatos P, Jass J, Wong N, Zaor S, Palma L, Kasprzak L, Tischkowitz M, Foulkes W. High frequency of exon deletions and putative founder effects in French Canadian Lynch syndrome families. Human Mutation 2009 May 20, (EPub ahead of print)